ロード中...
Radium-223 in metastatic castration resistant prostate cancer
In 2004, docetaxel was approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC). For the next several years, there was a lull in drug approvals. However, from 2010 onwards, 5 additional therapies have been approved on the basis of showing a survival benefit in phase III...
保存先:
| 主要な著者: | , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Medknow Publications & Media Pvt Ltd
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4023358/ https://ncbi.nlm.nih.gov/pubmed/24713838 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/1008-682X.127812 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|